Cangrelor in STEMI as a bridge to CABG- a mini-case series

Area of Science:

• Cardiology
• Pharmacology

Background:

• Patients with ST-elevation myocardial infarction (STEMI) require dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist.
• Some STEMI patients have multi-vessel disease necessitating urgent coronary artery bypass grafting (CABG).
• Oral P2Y12 inhibitors have prolonged effects, potentially delaying necessary CABG surgery due to bleeding risks.

Purpose of the Study:

• To evaluate the safety and efficacy of cangrelor in STEMI patients requiring emergent CABG.
• To assess if cangrelor administration impacts the timing of CABG surgery.

Main Methods:

• Retrospective case series of three STEMI patients.
• Patients received intravenous cangrelor as part of DAPT prior to cardiac catheterization.
• Coronary angiography identified multi-vessel disease requiring CABG.

Main Results:

• All three patients underwent successful CABG within 24-48 hours of cangrelor initiation.
• Cangrelor infusion was discontinued approximately one hour before surgery.
• No significant bleeding complications were reported, and patients experienced rapid recovery.

Conclusions:

• Cangrelor is a viable P2Y12 inhibitor for STEMI patients who may require urgent CABG.
• Its short half-life and rapid reversibility facilitate timely surgical intervention without compromising patient safety.